“We Don’t Even Get to ROI Without Clinical Impact”: Elevance and DiMe Discuss Raising the Bar in Digital Health
A behind-the-scenes look at how payers, providers, and startups are rethinking vendor evaluation with Elevance Health, DiMe, Perx Health, 2Morrow, and Alvida Health.
.jpg)
Last week, Perx Health joined the Digital Medicine Society (DiMe), Elevance Health, 2Morrow, and Alvida Health for a first-of-its-kind conversation about assessing clinical quality in digital health software.
With over 350,000 digital tools on the market, how do we know what works? What should payers and providers demand from their vendor partners? And how can startups build the right kind of evidence without draining their resources?
The conversation focused on three key questions:
- Why clinical effectiveness assessments matter
- What high-quality evidence actually looks like
- How to overcome the time and cost barriers of generating that evidence
Highlights from the Panel:
- "We believe evidence is critical. Clinical effectiveness is one of the best tools we have to predict what will improve member health." Jordan Silberman, Elevance Health
- "There are 350,000 solutions and only so many buyers. Evidence is how you stand out and survive." Scott Taylor, Perx Health
- "We didn't just chase studies for credibility. We built our evidence strategy around what underserved members actually need." Jo Masterson, 2Morrow
Why it Matters:
It’s no longer acceptable to rely on engagement stats or cherry-picked outcomes. Payers and providers want real-world impact, and they're aligning behind frameworks like the DiMe Seal to define what "good" looks like.
Watch the full recording here.
Unlock this piece of content
Thank you!
Here is the downloadable asset from this article
:
“We Don’t Even Get to ROI Without Clinical Impact”: Elevance and DiMe Discuss Raising the Bar in Digital Health
